Dentsply Sirona 3Q 2026: Revenue $836M, EPS ($0.01) — 10-Q Summary
Dentsply Sirona (XRAY) reported 3Q 2026 revenue of $836M, down 7.5% YoY, and a net loss of $2M, improved from a $427M loss last year. Sales declines were driven by lower implant volumes and reduced sales in certain regions, partially offset by higher Wellspect volumes. Gross margin increased to 52.9%. The company expects $60M–$65M in total restructuring charges with $100M in annualized savings.
How this was made
The 30-second read
Why it matters
The earnings miss and loss narrowing provide fresh data for traders to reassess valuation and near‑term price direction.
Market read
First disclosure of Q3 2026 financials; revenue down 7.5% YoY, loss narrowed, prompting likely short‑term downside.
What to watch
Higher Wellspect volumes and $100M annualized savings from restructuring may cushion earnings in upcoming quarters.
Background
Dentsply Sirona reported its Q3 2026 results via a 10‑Q filing, highlighting revenue decline, segment performance, and restructuring charges.
Market effects
Dental equipment sector may see broader scrutiny as implant volume weakness could affect peers.
U.S. dental device manufacturers could face short‑term sell pressure.
Limited to the dental equipment niche; no broad market impact.
Counterpoint
The narrowed loss and improved gross margin could be seen as a turnaround signal, supporting a short‑term bounce.
Key entities
- CompanyDentsply Sirona
U.S.-listed dental equipment manufacturer (ticker DENT).
